HIV-Neutralizing Polypeptides: A Novel Use for Platelet Factor 4 or Its Derivatives
The subject invention describes the method for using Platelet Factor 4 (PF4), also called CXCL4, to inhibit HIV viral entry by blocking GP120 independent of HIV receptor. It also demonstrates that the active polypeptide fragment(s) of PF-4 could be used to identify potential peptide mimics or small molecules that could be used to inhibit HIV infection. PF4 and/or its derivatives may be developed as a systemic therapy or preventive measure using topical applications, such as microbicides. In addition, CXCL4 serum/plasma testing could be used as a clinical marker of HIV disease status to predict/monitor the efficacy of treatment and determine the prognosis of a subject with HIV infection.
|Potential Commercial Applications:||Competitive Advantages:||
Paolo Lusso (NIAID)
David Auerbach (NIAID)
US Application No. 61/649,150
Sally Hu , Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 21
Rockville , MD 20852
OTT Reference No: E-140-2012/0